Do analysts rate DXRX or IDHC?

Diaceutics presently has a consensus price target of GBX 215, suggesting a potential upside of 41.45%. Given Diaceutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Diaceutics is more favorable than Integrated Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Integrated Diagnostics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor DXRX or IDHC?

In the previous week, Diaceutics had 1 more articles in the media than Integrated Diagnostics. MarketBeat recorded 2 mentions for Diaceutics and 1 mentions for Integrated Diagnostics. Integrated Diagnostics' average media sentiment score of 1.11 beat Diaceutics' score of 0.54 indicating that Integrated Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Diaceutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Integrated Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer MXCT or DXRX?

Diaceutics has a consensus target price of GBX 215, indicating a potential upside of 41.45%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts clearly believe Diaceutics is more favorable than MaxCyte. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MaxCyte 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger valuation and earnings, MXCT or DXRX?

Diaceutics has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MaxCyte £32.29M 0.04 -£45.08M -£40.00 N/A Diaceutics £38.44M 3.35 -£2.84M £0.11 1,381.82

Is MXCT or DXRX more profitable?

Diaceutics has a net margin of 0.25% compared to MaxCyte's net margin of -119.69%. Diaceutics' return on equity of 0.25% beat MaxCyte's return on equity. Company Net Margins Return on Equity Return on Assets MaxCyte -119.69% -11.59% -11.07% Diaceutics 0.25% 0.25% -6.06%

Do analysts prefer DXRX or ABDX?

Diaceutics presently has a consensus target price of GBX 215, suggesting a potential upside of 41.45%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts clearly believe Diaceutics is more favorable than Abingdon Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Abingdon Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer YGEN or DXRX?

Diaceutics has a consensus target price of GBX 215, indicating a potential upside of 41.45%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts plainly believe Diaceutics is more favorable than Yourgene Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Yourgene Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate DXRX or GDR?

Diaceutics presently has a consensus price target of GBX 215, indicating a potential upside of 41.45%. Given Diaceutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Diaceutics is more favorable than genedrive. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Diaceutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 genedrive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, DXRX or GDR?

Diaceutics has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Diaceutics £38.44M 3.35 -£2.84M £0.11 1,381.82 genedrive £929K 19.88 -£21.22M -£0.79 N/A

Is DXRX or GDR more profitable?

Diaceutics has a net margin of 0.25% compared to genedrive's net margin of -500.75%. Diaceutics' return on equity of 0.25% beat genedrive's return on equity. Company Net Margins Return on Equity Return on Assets Diaceutics 0.25% 0.25% -6.06% genedrive -500.75% -1,044.57% -74.09%

Does the media favor DXRX or GDR?

In the previous week, genedrive had 1 more articles in the media than Diaceutics. MarketBeat recorded 3 mentions for genedrive and 2 mentions for Diaceutics. Diaceutics' average media sentiment score of 0.54 beat genedrive's score of 0.37 indicating that Diaceutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Diaceutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive genedrive 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Diaceutics (DXRX) Competitors

GBX 152 +7.00 (+4.83%)

As of 10:52 AM Eastern

Compare

DXRX vs. IDHC, MXCT, ABDX, YGEN, and GDR

Should you buy Diaceutics stock or one of its competitors? MarketBeat compares Diaceutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Diaceutics include Integrated Diagnostics (IDHC), MaxCyte (MXCT), Abingdon Health (ABDX), Yourgene Health (YGEN), and genedrive (GDR). These companies are all part of the "life sciences tools & services" industry.

How does Diaceutics compare to Integrated Diagnostics?

Diaceutics (LON:DXRX) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Diaceutics presently has a consensus price target of GBX 215, suggesting a potential upside of 41.45%. Given Diaceutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Diaceutics is more favorable than Integrated Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Integrated Diagnostics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Diaceutics had 1 more articles in the media than Integrated Diagnostics. MarketBeat recorded 2 mentions for Diaceutics and 1 mentions for Integrated Diagnostics. Integrated Diagnostics' average media sentiment score of 1.11 beat Diaceutics' score of 0.54 indicating that Integrated Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Diaceutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Integrated Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

32.6% of Diaceutics shares are owned by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are owned by institutional investors. 26.3% of Diaceutics shares are owned by company insiders. Comparatively, 71.3% of Integrated Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Diaceutics has a beta of 0.889, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.376, suggesting that its share price is 62% less volatile than the broader market.

Integrated Diagnostics has higher revenue and earnings than Diaceutics. Integrated Diagnostics is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diaceutics	£38.44M	3.35	-£2.84M	£0.11	1,381.82
Integrated Diagnostics	£8.35B	0.00	£4.01T	£250.03	0.00

Integrated Diagnostics has a net margin of 17.20% compared to Diaceutics' net margin of 0.25%. Integrated Diagnostics' return on equity of 38.79% beat Diaceutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Diaceutics	0.25%	0.25%	-6.06%
Integrated Diagnostics	17.20%	38.79%	9.69%

Summary

Diaceutics and Integrated Diagnostics tied by winning 8 of the 16 factors compared between the two stocks.

How does Diaceutics compare to MaxCyte?

MaxCyte (LON:MXCT) and Diaceutics (LON:DXRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

24.0% of MaxCyte shares are owned by institutional investors. Comparatively, 32.6% of Diaceutics shares are owned by institutional investors. 1.9% of MaxCyte shares are owned by insiders. Comparatively, 26.3% of Diaceutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Diaceutics has a net margin of 0.25% compared to MaxCyte's net margin of -119.69%. Diaceutics' return on equity of 0.25% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-119.69%	-11.59%	-11.07%
Diaceutics	0.25%	0.25%	-6.06%

Diaceutics has a consensus target price of GBX 215, indicating a potential upside of 41.45%. Given Diaceutics' stronger consensus rating and higher probable upside, analysts clearly believe Diaceutics is more favorable than MaxCyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

MaxCyte has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Diaceutics has a beta of 0.889, indicating that its stock price is 11% less volatile than the broader market.

In the previous week, Diaceutics had 2 more articles in the media than MaxCyte. MarketBeat recorded 2 mentions for Diaceutics and 0 mentions for MaxCyte. Diaceutics' average media sentiment score of 0.54 beat MaxCyte's score of 0.00 indicating that Diaceutics is being referred to more favorably in the news media.

Company	Overall Sentiment
MaxCyte	Neutral
Diaceutics	Positive

Diaceutics has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	£32.29M	0.04	-£45.08M	-£40.00	N/A
Diaceutics	£38.44M	3.35	-£2.84M	£0.11	1,381.82

Summary

Diaceutics beats MaxCyte on 15 of the 16 factors compared between the two stocks.

How does Diaceutics compare to Abingdon Health?

Diaceutics (LON:DXRX) and Abingdon Health (LON:ABDX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Diaceutics has a beta of 0.889, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Abingdon Health has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

In the previous week, Diaceutics had 2 more articles in the media than Abingdon Health. MarketBeat recorded 2 mentions for Diaceutics and 0 mentions for Abingdon Health. Abingdon Health's average media sentiment score of 0.76 beat Diaceutics' score of 0.54 indicating that Abingdon Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Diaceutics	Positive
Abingdon Health	Positive

Abingdon Health has lower revenue, but higher earnings than Diaceutics. Abingdon Health is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diaceutics	£38.44M	3.35	-£2.84M	£0.11	1,381.82
Abingdon Health	£9.57M	2.83	-£796.37K	-£0.81	N/A

Diaceutics presently has a consensus target price of GBX 215, suggesting a potential upside of 41.45%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts clearly believe Diaceutics is more favorable than Abingdon Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Abingdon Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Diaceutics has a net margin of 0.25% compared to Abingdon Health's net margin of -33.88%. Diaceutics' return on equity of 0.25% beat Abingdon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Diaceutics	0.25%	0.25%	-6.06%
Abingdon Health	-33.88%	-55.91%	-17.93%

32.6% of Diaceutics shares are held by institutional investors. Comparatively, 3.7% of Abingdon Health shares are held by institutional investors. 26.3% of Diaceutics shares are held by insiders. Comparatively, 8.0% of Abingdon Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Diaceutics beats Abingdon Health on 14 of the 16 factors compared between the two stocks.

How does Diaceutics compare to Yourgene Health?

Yourgene Health (LON:YGEN) and Diaceutics (LON:DXRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Diaceutics has a consensus target price of GBX 215, indicating a potential upside of 41.45%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts plainly believe Diaceutics is more favorable than Yourgene Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yourgene Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

23.3% of Yourgene Health shares are held by institutional investors. Comparatively, 32.6% of Diaceutics shares are held by institutional investors. 64.4% of Yourgene Health shares are held by company insiders. Comparatively, 26.3% of Diaceutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Diaceutics has higher revenue and earnings than Yourgene Health. Yourgene Health is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yourgene Health	£29.67M	0.00	-£8.17M	-£0.01	N/A
Diaceutics	£38.44M	3.35	-£2.84M	£0.11	1,381.82

Diaceutics has a net margin of 0.25% compared to Yourgene Health's net margin of -27.55%. Diaceutics' return on equity of 0.25% beat Yourgene Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yourgene Health	-27.55%	-27.06%	-6.71%
Diaceutics	0.25%	0.25%	-6.06%

In the previous week, Diaceutics had 2 more articles in the media than Yourgene Health. MarketBeat recorded 2 mentions for Diaceutics and 0 mentions for Yourgene Health. Diaceutics' average media sentiment score of 0.54 beat Yourgene Health's score of 0.00 indicating that Diaceutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Yourgene Health	Neutral
Diaceutics	Positive

Yourgene Health has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Diaceutics has a beta of 0.889, suggesting that its stock price is 11% less volatile than the broader market.

Summary

Diaceutics beats Yourgene Health on 14 of the 15 factors compared between the two stocks.

How does Diaceutics compare to genedrive?

Diaceutics (LON:DXRX) and genedrive (LON:GDR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

32.6% of Diaceutics shares are held by institutional investors. Comparatively, 0.1% of genedrive shares are held by institutional investors. 26.3% of Diaceutics shares are held by company insiders. Comparatively, 29.0% of genedrive shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Diaceutics has a net margin of 0.25% compared to genedrive's net margin of -500.75%. Diaceutics' return on equity of 0.25% beat genedrive's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Diaceutics	0.25%	0.25%	-6.06%
genedrive	-500.75%	-1,044.57%	-74.09%

Diaceutics has a beta of 0.889, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, genedrive has a beta of 0.989, suggesting that its stock price is 1% less volatile than the broader market.

In the previous week, genedrive had 1 more articles in the media than Diaceutics. MarketBeat recorded 3 mentions for genedrive and 2 mentions for Diaceutics. Diaceutics' average media sentiment score of 0.54 beat genedrive's score of 0.37 indicating that Diaceutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Diaceutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
genedrive	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Diaceutics has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diaceutics	£38.44M	3.35	-£2.84M	£0.11	1,381.82
genedrive	£929K	19.88	-£21.22M	-£0.79	N/A

Diaceutics presently has a consensus price target of GBX 215, indicating a potential upside of 41.45%. Given Diaceutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Diaceutics is more favorable than genedrive.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
genedrive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Diaceutics beats genedrive on 12 of the 16 factors compared between the two stocks.

Get Diaceutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXRX vs. The Competition

Export

Metric	Diaceutics	Life Sciences Tools & Services Industry	Healthcare Sector	LON Exchange
Market Cap	£128.64M	£9.22B	£6.93B	£2.87B
Dividend Yield	N/A	1.47%	2.60%	6.13%
P/E Ratio	1,381.82	62.26	281.16	369.49
Price / Sales	3.35	260.94	576.65	83,955.53
Price / Cash	3.12	25.96	71.79	27.89
Price / Book	3.31	38.11	12.86	7.07
Net Income	-£2.84M	£57.47B	£3.49B	£5.89B
7 Day Performance	10.14%	1.35%	2.65%	1.18%
1 Month Performance	4.83%	-2.30%	-2.63%	0.90%
1 Year Performance	11.67%	19.18%	76.00%	75.31%

Diaceutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXRX Diaceutics	1.9997 of 5 stars	GBX 152 +4.8%	GBX 215 +41.4%	+4.4%	£128.64M	£38.44M	1,381.82	151
IDHC Integrated Diagnostics	N/A	GBX 0.55 -5.8%	N/A	+56.4%	£339.49M	£8.35B	0.00	6,692	Gap Down
MXCT MaxCyte	N/A	GBX 1.05 +4.0%	N/A	-47.5%	£170.11M	£32.29M	N/A	80	High Trading Volume
ABDX Abingdon Health	N/A	GBX 11 +7.3%	N/A	+61.4%	£25.74M	£9.57M	N/A	84	Gap Down
YGEN Yourgene Health	N/A	N/A	N/A	N/A	£16.43M	£29.67M	N/A	253

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:DXRX) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Diaceutics (DXRX) Competitors

DXRX vs. IDHC, MXCT, ABDX, YGEN, and GDR

How does Diaceutics compare to Integrated Diagnostics?

Summary

How does Diaceutics compare to MaxCyte?

Summary

How does Diaceutics compare to Abingdon Health?

Summary

How does Diaceutics compare to Yourgene Health?

Summary

How does Diaceutics compare to genedrive?

Summary

Media Sentiment Over Time

DXRX vs. The Competition

Diaceutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Diaceutics (DXRX) Competitors

DXRX vs. IDHC, MXCT, ABDX, YGEN, and GDR

How does Diaceutics compare to Integrated Diagnostics?

Do analysts rate DXRX or IDHC?

Does the media favor DXRX or IDHC?

Do institutionals and insiders have more ownership in DXRX or IDHC?

Which has more volatility & risk, DXRX or IDHC?

Which has stronger valuation and earnings, DXRX or IDHC?

Is DXRX or IDHC more profitable?

Summary

How does Diaceutics compare to MaxCyte?

Do insiders & institutionals believe in MXCT or DXRX?

Is MXCT or DXRX more profitable?

Do analysts prefer MXCT or DXRX?

Which has more risk and volatility, MXCT or DXRX?

Does the media refer more to MXCT or DXRX?

Which has stronger valuation and earnings, MXCT or DXRX?

Summary

How does Diaceutics compare to Abingdon Health?

Which has more volatility & risk, DXRX or ABDX?

Does the media favor DXRX or ABDX?

Which has better earnings & valuation, DXRX or ABDX?

Do analysts prefer DXRX or ABDX?

Is DXRX or ABDX more profitable?

Do insiders & institutionals believe in DXRX or ABDX?

Summary

How does Diaceutics compare to Yourgene Health?

Do analysts prefer YGEN or DXRX?

Do insiders and institutionals believe in YGEN or DXRX?

Which has better valuation and earnings, YGEN or DXRX?

Is YGEN or DXRX more profitable?

Does the media prefer YGEN or DXRX?

Which has more volatility and risk, YGEN or DXRX?

Summary

How does Diaceutics compare to genedrive?

Do institutionals & insiders have more ownership in DXRX or GDR?

Is DXRX or GDR more profitable?

Which has more volatility and risk, DXRX or GDR?

Does the media favor DXRX or GDR?

Which has stronger valuation and earnings, DXRX or GDR?

Do analysts rate DXRX or GDR?

Summary

Media Sentiment Over Time

DXRX vs. The Competition

Diaceutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools